As a result, professional practice guidelines now recommend NSCLC patients with high (≥50% TPS) PD-L1 IHC expression receive frontline pembrolizumab monotherapy, while patients with low (≥1% TPS) or negative (<1% TPS) PD-L1 IHC expression receive combination pembrolizumab plus chemotherapy, in contradiction to the FDA label indication [22]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.